Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CND002
MIFTS: 54

Conduct Disorder

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Conduct Disorder

About this section

MalaCards integrated aliases for Conduct Disorder:

Name: Conduct Disorder 12 76 55 44 15 73

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:12995
ICD10 33 F91 F91.9
ICD9CM 35 312.9
MeSH 44 D019955
NCIt 50 C89329
UMLS 73 C0149654
Sources

Summaries for Conduct Disorder

About this section
Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to impulse control disorder and oppositional defiant disorder. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Dopamine and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and skin, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Sources

Related Diseases for Conduct Disorder

About this section

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 33.1 DRD2 DRD4
2 oppositional defiant disorder 30.8 COMT DBH DRD2 DRD4 MAOA SLC6A3
3 depression 30.8 MAOA SLC6A4 TPH1
4 anxiety 30.2 COMT MAOA SLC6A4 TPH1
5 borderline personality disorder 29.7 COMT MAOA SLC6A4 TPH1
6 alcohol abuse 29.5 ALDH2 DRD2 DRD4 SLC6A4
7 tic disorder 29.2 DRD2 DRD4 DRD5 SLC6A3
8 antisocial personality disorder 29.1 ALDH2 COMT DRD2 MAOA SLC6A3 SLC6A4
9 autism spectrum disorder 29.1 OXTR RBFOX1 SLC6A4
10 substance dependence 28.9 DRD2 DRD4 DRD5 MAOA SLC6A3 SLC6A4
11 major depressive disorder 28.2 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
12 gilles de la tourette syndrome 28.2 COMT DBH DRD2 DRD4 DRD5 SLC6A3
13 personality disorder 28.1 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
14 substance abuse 28.0 COMT DBH DRD2 DRD4 DRD5 MAOA
15 autism 27.9 COMT DRD2 DRD4 MAOA OXTR RBFOX1
16 tobacco addiction 27.9 ALDH2 COMT DRD2 MAOA SLC6A3 TPH1
17 panic disorder 27.8 ADORA2A COMT MAOA SLC6A4 TPH1
18 disease of mental health 27.4 ALDH2 COMT DRD2 DRD4 MAOA OXTR
19 attention deficit-hyperactivity disorder 27.1 COMT DBH DRD2 DRD4 DRD5 MAOA
20 alcohol dependence 26.2 ALDH2 COMT DBH DRD2 DRD4 GRIN1
21 bipolar disorder 26.1 COMT DBH DRD2 DRD4 DRD5 GRIN1
22 schizophrenia 24.6 ADORA2A COMT DBH DRD2 DRD4 DRD5
23 heart conduction disease 11.2
24 cardiomyopathy, dilated, 1e 11.1
25 familial progressive cardiac conduction defect 10.9
26 wolff-parkinson-white syndrome 10.9
27 progressive familial heart block, type ia 10.9
28 cardiac conduction defect 10.9
29 atypical depressive disorder 10.7 MAOA SLC6A4
30 delusional disorder 10.7 DRD2 DRD4
31 phobia, specific 10.6 COMT MAOA
32 schizophreniform disorder 10.6 COMT DRD2
33 polysubstance abuse 10.6 COMT DRD2
34 tardive dyskinesia 10.6 COMT DRD2
35 dependent personality disorder 10.5 DRD4 MAOA
36 premature ejaculation 10.5 COMT SLC6A3 SLC6A4
37 alcohol-induced mental disorder 10.5 DRD2 SLC6A3 SLC6A4
38 alcoholic psychosis 10.5 DRD2 SLC6A3 SLC6A4
39 dysthymic disorder 10.5 MAOA SLC6A4
40 migraine without aura 10.5 DRD2 DRD4 SLC6A4
41 kleptomania 10.5 MAOA SLC6A4
42 phobic disorder 10.5 COMT MAOA SLC6A4
43 social phobia 10.4 DRD2 MAOA SLC6A4
44 paranoid schizophrenia 10.4 COMT MAOA SLC6A4
45 striatonigral degeneration 10.4 DRD2 SLC6A3
46 separation anxiety disorder 10.4 DRD4 OXTR SLC6A3
47 schizoaffective disorder 10.4 COMT DRD2 SLC6A4
48 bulimia nervosa 10.4 COMT MAOA SLC6A4
49 periodic limb movement disorder 10.4 DRD2 SLC6A4
50 chronic fatigue syndrome 10.4 COMT MAOA SLC6A4

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder
Sources

Symptoms & Phenotypes for Conduct Disorder

About this section

MGI Mouse Phenotypes related to Conduct Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.35 SLC6A3 SLC6A4 MAOA OXTR TPH1 RBFOX1
2 homeostasis/metabolism MP:0005376 10.18 SLC6A3 SLC6A4 MAOA TPH1 RBFOX1 COMT
3 cardiovascular system MP:0005385 10.11 SLC6A4 MAOA TPH1 DRD5 COMT GRIN1
4 growth/size/body region MP:0005378 10.1 SLC6A3 SLC6A4 OXTR TPH1 RBFOX1 GRIN1
5 endocrine/exocrine gland MP:0005379 10.03 SLC6A3 SLC6A4 OXTR DRD5 COMT DBH
6 nervous system MP:0003631 10 SLC6A3 SLC6A4 MAOA OXTR RBFOX1 DRD5
7 integument MP:0010771 9.97 SLC6A3 SLC6A4 OXTR TPH1 DBH ADORA2A
8 muscle MP:0005369 9.73 SLC6A3 SLC6A4 OXTR TPH1 ADORA2A DRD2
9 normal MP:0002873 9.5 SLC6A3 SLC6A4 OXTR DRD5 GRIN1 DBH
10 reproductive system MP:0005389 9.17 SLC6A3 GRIN1 OXTR RBFOX1 COMT DRD2
Sources

Drugs & Therapeutics for Conduct Disorder

About this section

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
5
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113-45-1 4158
6
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
7
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
8
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
11
Carbidopa Approved Phase 4 28860-95-9 34359 38101
12
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
13
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
14
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
15
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
16
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
17
Citalopram Approved Phase 4 59729-33-8 2771
18
Levodopa Approved Phase 4 59-92-7 6047
19
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 5826 3007
20
Oxcarbazepine Approved Phase 4 28721-07-5 34312
21
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
22
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
25 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 GABA Agents Phase 4
27 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Serotonin Antagonists Phase 4,Phase 3,Phase 2
29 Neuroprotective Agents Phase 4,Phase 2
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Dopamine Antagonists Phase 4,Phase 3,Phase 2
35 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Anticonvulsants Phase 4,Phase 2
37 Anti-Obesity Agents Phase 4,Phase 2
38 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
41 Antimanic Agents Phase 4,Phase 3
42 Analgesics Phase 4,Phase 2
43 Dopamine agonists Phase 4,Phase 3,Phase 1
44 Adrenergic Agents Phase 4,Phase 2
45 Adrenergic Agonists Phase 4
46 Adrenergic alpha-2 Receptor Agonists Phase 4
47 Adrenergic alpha-Agonists Phase 4
48 Cholinergic Agents Phase 4,Phase 2,Not Applicable
49 Muscarinic Antagonists Phase 4
50 Cholinergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
4 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
5 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States. Completed NCT00154362 Phase 4 Oxcarbazepine
6 Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
7 Early Prevention of Conduct Problems Completed NCT00051714 Phase 4
8 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
9 Treatment of Severe Childhood Aggression (The TOSCA Study) Completed NCT00796302 Phase 4 Methylphenidate HCl;Risperidone;Placebo
10 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
11 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
12 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
13 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
14 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
15 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
16 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
17 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
18 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
19 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
20 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? Completed NCT01127607 Phase 4 lisdexamfetamine
21 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
22 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
23 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
24 Multidimensional Treatment Foster Care for Adolescents Withdrawn NCT01726361 Phase 4
25 Long-Term Lithium Treatment for Aggressive Conduct Disorder Completed NCT00000385 Phase 3 Lithium;Placebo
26 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
27 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
28 Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth Completed NCT01594606 Phase 3
29 Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders Completed NCT00618943 Phase 3
30 Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse Completed NCT00776685 Phase 2, Phase 3
31 Personality-targeted Interventions for Adolescent Alcohol Misuse Completed NCT00344474 Phase 2, Phase 3
32 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
33 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
34 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
35 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
36 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
37 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
38 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
39 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
40 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
41 Dronabinol in Trichotillomania Not yet recruiting NCT03530800 Phase 2, Phase 3 Dronabinol;Placebo
42 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease Not yet recruiting NCT03146130 Phase 3
43 How the Adolescent Inpatients Are Rehabilitated After Discharge Terminated NCT01709526 Phase 2, Phase 3
44 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 Edivoxetine
45 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
46 Testing a New Therapy for Trichotillomania Unknown status NCT00872742 Phase 2
47 Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling Unknown status NCT01529047 Phase 2
48 Prevention of School Dropout for Mexican American Adolescents Completed NCT00051727 Phase 2
49 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
50 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: conduct disorder

Sources

Genetic Tests for Conduct Disorder

About this section
Sources

Anatomical Context for Conduct Disorder

About this section

MalaCards organs/tissues related to Conduct Disorder:

41
Brain, Testes, Skin, Amygdala, Cortex, Fetal Brain, Temporal Lobe
Sources

Publications for Conduct Disorder

About this section

Articles related to Conduct Disorder:

(show top 50) (show all 688)
# Title Authors Year
1
Assessment of the frequency criterion for the diagnosis of non-suicidal self-injury disorder in female adolescents with conduct disorder. ( 29957550 )
2018
2
Episodic memory and consciousness in antisocial personality disorder and conduct disorder. ( 29353574 )
2018
3
Conduct disorder in adolescent females: current state of research and study design of the FemNAT-CD consortium. ( 29948230 )
2018
4
Conduct Disorder and Neighborhood Effects. ( 29350996 )
2018
5
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
6
MAOA genotype influences neural response during an inhibitory task in adolescents with conduct disorder. ( 29855796 )
2018
7
Does the course of manic symptoms in pediatric bipolar disorder impact the course of conduct disorder? Findings from four prospective datasets. ( 29890451 )
2018
8
A longitudinal analysis of shooter games and their relationship with conduct disorder and cself-reported delinquency. ( 29853012 )
2018
9
Social skills training and play group intervention for children with oppositional-defiant disorders/conduct disorder: Mediating mechanisms in a head-to-head comparison. ( 29347904 )
2018
10
Distinguishing Adolescents With Conduct Disorder From Typically Developing Youngsters Based on Pattern Classification of Brain Structural MRI. ( 29740296 )
2018
11
Sex Differences in the Genetic and Environmental Influences on Self-Reported Non-aggressive and Aggressive Conduct Disorder Symptoms in Early and Middle Adolescence. ( 29948512 )
2018
12
Pregnancy risk factors in relation to oppositional-defiant and conduct disorder symptoms in the Avon Longitudinal Study of Parents and Children. ( 29550610 )
2018
13
Do Callous-Unemotional Traits and Conduct Disorder Symptoms Predict the Onset and Development of Adolescent Substance Use? ( 29455341 )
2018
14
Oppositional defiant disorder/conduct disorder co-occurrence increases the risk of Internet addiction in adolescents with attention-deficit hyperactivity disorder. ( 29865863 )
2018
15
Anatomy of the dorsal default-mode network in conduct disorder: Association with callous-unemotional traits. ( 29413533 )
2018
16
Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder. ( 29348532 )
2018
17
Reciprocal Relations Between Parenting Behaviors and Conduct Disorder Symptoms in Preschool Children. ( 29468356 )
2018
18
Serum levels of cortisol, dehydroepiandrosterone, and oxytocin in children with attention-deficit/hyperactivity disorder combined presentation with and without comorbid conduct disorder. ( 29324397 )
2018
19
A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder. ( 29073744 )
2017
20
Conduct Disorder ( 29261891 )
2017
21
Sex differences in risk-based decision making in adolescents with conduct disorder. ( 28688012 )
2017
22
Affect recognition among adolescents in therapeutic schools: relationships with posttraumatic stress disorder and conduct disorder symptoms. ( 28503096 )
2017
23
Disrupted small-world brain network topology in pure conduct disorder. ( 29029449 )
2017
24
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
25
Spiritual Psychotherapy for Adolescents with Conduct Disorder: Designing and Piloting a Therapeutic Package. ( 29472952 )
2017
26
Sex Differences in the Relationship Between Conduct Disorder and Cortical Structure inA Adolescents. ( 28735700 )
2017
27
Short- and long-range functional connectivity density alterations in adolescents with pure conduct disorder at resting-state. ( 28377176 )
2017
28
The reliability, concurrent validity and association with salivary oxytocin of the self-report version of the Inventory of Callous-Unemotional Traits in adolescents with conduct disorder. ( 28628793 )
2017
29
Familial early infantile epileptic encephalopathy and cardiac conduction disorder: A rare cause of SUDEP in infancy. ( 28697420 )
2017
30
Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence. ( 28695488 )
2017
31
Population cost-effectiveness of the Triple P parenting programme for the treatment of conduct disorder: an economic modelling study. ( 29288334 )
2017
32
Associations between a history of traumatic brain injuries and conduct disorder during youth in a population sample of Canadian adults. ( 28867408 )
2017
33
Community Violence Exposure and Conduct Problems in Children and Adolescents with Conduct Disorder and Healthy Controls. ( 29163090 )
2017
34
Mental health among young adults in prison: the importance of childhood-onset conduct disorder. ( 28357134 )
2017
35
Differential neuropsychological functioning between adolescents with attention-deficit/hyperactivity disorder with and without conduct disorder. ( 28292624 )
2017
36
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
37
A systematic review on the prevalence of conduct disorder in the Middle East. ( 28681265 )
2017
38
Hiccup Due to Aripiprazole Plus Methylphenidate Treatment in an Adolescent with Attention Deficit and Hyperactivity Disorder and Conduct Disorder: A Case Report. ( 29073754 )
2017
39
Empathic skills and theory of mind in female adolescents with conduct disorder. ( 28614490 )
2017
40
Neurocognitive characteristics of youth with noncomorbid and comorbid forms of conduct disorder and attention deficit hyperactivity disorder. ( 28636895 )
2017
41
Investigation of the Changes in the Power Distribution in Resting-State Brain Networks Associated with Pure Conduct Disorder. ( 28717223 )
2017
42
Taxometric analyses and predictive accuracy of callous-unemotional traits regarding quality of life and behavior problems in non-conduct disorder diagnoses. ( 28427034 )
2017
43
Conduct Disorder Symptoms and Illicit Drug Use in Juvenile Justice Involved Youth: The Reciprocal Relationship Between Positive Illicit Drug-Use Attitudes and Illicit Drug Use. ( 29185888 )
2017
44
Facial emotion recognition and eye movement behaviour in conduct disorder. ( 28881001 )
2017
45
Implicit Attitudes Toward Violence in a Sample of Adolescent Offenders With Conduct Disorder. ( 29294969 )
2017
46
Altered White-Matter Microstructure in Conduct Disorder Is Specifically Associated with Elevated Callous-Unemotional Traits. ( 29273881 )
2017
47
Alterations of Brain Functional Architecture Associated with Psychopathic Traits in Male Adolescents with Conduct Disorder. ( 28900210 )
2017
48
Transitions and Motivations for Substance Misuse in Prison Inmates With ADHD and Conduct Disorder: Validation of a New Instrument. ( 28418789 )
2017
49
Body Mass Index z-Scores and Weight Status Predict Conduct Disorder Symptoms in Adolescents. ( 28867351 )
2017
50
Comorbidities and correlates of conduct disorder among male juvenile detainees in South Korea. ( 28924450 )
2017
Sources

Variations for Conduct Disorder

About this section
Sources

Expression for Conduct Disorder

About this section
Search GEO for disease gene expression data for Conduct Disorder.
Sources

Pathways for Conduct Disorder

About this section

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Transmission across Chemical Synapses 66
Show member pathways
 12.86 ALDH2 CAMK2A COMT GRIN1 MAOA SLC6A3
2
Circadian entrainment 37
Show member pathways
 12.79 CAMK2A COMT DRD2 DRD4 DRD5 GRIN1
3
Neuroscience 4
12.46 CAMK2A COMT DBH GRIN1 TPH1
4
Dopamine-DARPP32 Feedback onto cAMP Pathway 64
12.21 DRD2 DRD4 DRD5 GRIN1
6
Calcium signaling pathway 37
Show member pathways
 12.1 ADORA2A CAMK2A DRD5 GRIN1 OXTR
7
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.05 GRIN1 MAOA SLC6A4 TPH1
8
cAMP signaling pathway 37
Show member pathways
 12.04 ADORA2A CAMK2A DRD2 DRD5 GRIN1 OXTR
9
Long-term potentiation 37
Show member pathways
 12.02 CAMK2A DRD2 DRD4 DRD5 GRIN1
10
Monoamine GPCRs 1
Show member pathways
 11.84 DRD2 DRD4 DRD5
11
Serotonergic synapse 37
11.83 MAOA SLC6A4 TPH1
12
Amphetamine addiction 37
Show member pathways
 11.83 CAMK2A DRD2 GRIN1 MAOA SLC6A3
13
Amino Acid metabolism 1
11.71 DBH MAOA TPH1
14
Tyrosine metabolism 37
Show member pathways
 11.62 COMT DBH MAOA
15
MECP2 and Associated Rett Syndrome 1
11.52 CAMK2A GRIN1 RBFOX1
16
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 61
11.13 MAOA SLC6A4 TPH1
17
Monoamine Transport 1
Show member pathways
 10.99 ADORA2A DBH MAOA SLC6A3 SLC6A4
18
DARPP-32 Phosphorylation 65
10.95 DRD2 DRD5
19
noradrenaline and adrenaline degradation 1
Show member pathways
 10.83 ALDH2 COMT MAOA
20
Biogenic Amine Synthesis 1
Show member pathways
 10.8 COMT DBH MAOA TPH1
21
Dopamine metabolism 1
10.74 COMT MAOA
22
putrescine degradation III 1
Show member pathways
 10.7 ALDH2 MAOA
23
Neurotransmitter Clearance In The Synaptic Cleft 66
Show member pathways
 10.44 ALDH2 COMT MAOA SLC6A3 SLC6A4
Sources

GO Terms for Conduct Disorder

About this section

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.71 ADORA2A COMT DRD2 GRIN1
2 axon GO:0030424 9.62 ADORA2A COMT DRD2 SLC6A3
3 dendritic spine GO:0043197 9.54 COMT DRD2 GRIN1
4 non-motile cilium GO:0097730 9.46 DRD2 DRD5
5 postsynaptic density GO:0014069 9.46 ADORA2A CAMK2A DRD2 GRIN1
6 neuron projection GO:0043005 9.35 CAMK2A GRIN1 SLC6A3 SLC6A4 TPH1
7 integral component of plasma membrane GO:0005887 9.23 ADORA2A DRD2 DRD4 DRD5 GRIN1 OXTR
8 plasma membrane GO:0005886 10.13 ADORA2A CAMK2A COMT DRD2 DRD4 DRD5
9 integral component of membrane GO:0016021 10 ADORA2A COMT DBH DRD2 DRD4 DRD5

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.86 COMT OXTR SLC6A3
2 response to ethanol GO:0045471 9.85 DRD2 GRIN1 SLC6A3
3 response to drug GO:0042493 9.85 ADORA2A COMT DRD2 OXTR SLC6A3 SLC6A4
4 cellular calcium ion homeostasis GO:0006874 9.83 DRD4 DRD5 GRIN1
5 locomotory behavior GO:0007626 9.81 ADORA2A DBH DRD2 SLC6A3
6 excitatory postsynaptic potential GO:0060079 9.79 ADORA2A DRD2 GRIN1
7 learning GO:0007612 9.77 COMT DRD5 GRIN1
8 memory GO:0007613 9.76 DBH GRIN1 OXTR SLC6A4
9 visual learning GO:0008542 9.74 DBH DRD2 GRIN1
10 eating behavior GO:0042755 9.71 ADORA2A OXTR
11 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.71 ADORA2A OXTR
12 social behavior GO:0035176 9.71 DRD4 GRIN1 OXTR SLC6A4
13 arachidonic acid secretion GO:0050482 9.7 DRD2 DRD4
14 behavioral response to cocaine GO:0048148 9.7 DRD2 DRD4
15 regulation of long-term neuronal synaptic plasticity GO:0048169 9.7 DRD2 GRIN1
16 response to pain GO:0048265 9.7 COMT DBH
17 dopamine receptor signaling pathway GO:0007212 9.7 DRD2 DRD4 DRD5
18 regulation of neuronal synaptic plasticity GO:0048168 9.69 CAMK2A GRIN1
19 response to iron ion GO:0010039 9.69 DRD2 SLC6A3
20 negative regulation of protein secretion GO:0050709 9.68 DRD2 DRD4
21 startle response GO:0001964 9.68 DRD2 GRIN1
22 positive regulation of renal sodium excretion GO:0035815 9.68 ADORA2A DRD2
23 neurotransmitter biosynthetic process GO:0042136 9.67 SLC6A3 SLC6A4
24 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.67 DRD2 DRD5
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD2 DRD4
26 synaptic transmission, dopaminergic GO:0001963 9.67 ADORA2A DRD2 DRD5
27 positive regulation of urine volume GO:0035810 9.66 ADORA2A DRD2
28 maternal behavior GO:0042711 9.66 DBH OXTR
29 suckling behavior GO:0001967 9.65 GRIN1 OXTR
30 positive regulation of synaptic transmission, GABAergic GO:0032230 9.65 ADORA2A OXTR
31 behavioral response to ethanol GO:0048149 9.65 DBH DRD2 DRD4
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.64 DRD2 DRD4
33 neurotransmitter catabolic process GO:0042135 9.64 COMT MAOA
34 catecholamine metabolic process GO:0006584 9.63 COMT MAOA
35 regulation of dopamine metabolic process GO:0042053 9.63 DRD4 SLC6A3
36 monoamine transport GO:0015844 9.62 SLC6A3 SLC6A4
37 adenohypophysis development GO:0021984 9.62 DRD2 SLC6A3
38 response to cocaine GO:0042220 9.62 DRD2 DRD5 OXTR SLC6A3
39 inhibitory postsynaptic potential GO:0060080 9.61 ADORA2A DRD4
40 dopamine metabolic process GO:0042417 9.61 COMT DRD2 DRD4
41 dopamine uptake involved in synaptic transmission GO:0051583 9.59 SLC6A3 SLC6A4
42 sperm ejaculation GO:0042713 9.58 OXTR SLC6A4
43 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.58 DRD5 OXTR
44 fear response GO:0042596 9.56 DBH DRD4
45 associative learning GO:0008306 9.56 DBH DRD2 DRD5 GRIN1
46 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.55 DRD2 DRD4
47 response to histamine GO:0034776 9.54 DRD2 DRD4
48 prepulse inhibition GO:0060134 9.46 ADORA2A DRD2 GRIN1 SLC6A3
49 dopamine catabolic process GO:0042420 9.26 COMT DBH MAOA SLC6A3
50 response to amphetamine GO:0001975 9.17 ADORA2A DBH DRD2 DRD4 DRD5 GRIN1

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 ADORA2A DRD2 DRD4 DRD5 OXTR
2 obsolete signal transducer activity GO:0004871 9.65 ADORA2A DRD2 DRD4 DRD5 OXTR
3 drug binding GO:0008144 9.54 DRD2 DRD4 SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD4
6 monoamine transmembrane transporter activity GO:0008504 9.32 SLC6A3 SLC6A4
7 dopamine:sodium symporter activity GO:0005330 9.16 SLC6A3 SLC6A4
8 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
9 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3
Sources

Sources for Conduct Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....